Matthew D. Hall

TL;DR: Evidence is presented indicating that it is time to revisit the investigation into the role of ABC transporters in efficient drug delivery in various cancer types and at the blood–brain barrier, and push forward their clinical application as biomarkers and as targets in combination therapies in order to improve anticancer drug efficiency.

TL;DR: Decreased accumulation is one of the most common features resulting in cisplatin resistance, and seems to be a consequence of numerous epigenetic and genetic changes leading to the loss of cell-surface binding sites and/or transporters for cisPlatin, and decreased fluid phase endocytosis.

TL;DR: An overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness is provided.

TL;DR: A review of the investigations undertaken into platinum-IV antitumour compounds since Barnett Rosenberg first noted the activity of platinum(IV) complexes is given in this article. But the bioinorganic chemistry of these compounds has not previously been reviewed, and the purpose here is to provide insight into the requirements for the antitumours activity of these complexes.

TL;DR: A model that helps reconcile the disparate literature by describing multiple pathways for Pt-containing drugs into and out of the cell is suggested.